Endeavour Mining PLC (LSE:EDV, TSX:EDV, OTCQX:EDVMF) has had a 'buy' rating reiterated by broker Stifel after the first gold pour at its new Lafigué mine in Côte d'Ivoire.
The project is the company's fifth successful build in West Africa over the last decade, reaching production on budget and ahead of schedule, just 21 months after the construction launch, noted the broker.
JP Morgan analysts have reiterated their positive outlook on UK banks, particularly highlighting NatWest Group PLC (LSE:NWG) and Barclays PLC (LSE:BARC) as top picks in the sector.
After meetings with senior leadership for the leading operators, it highlighted the duo because of their resilient profit margins, strong cash generation, and high returns.
The plan by Marwyn Acquisition Company II Ltd (LSE:MAC2) to build the UK’s leading specialist pensions administrator offers "strong value creation ahead", said broker Panmure Liberum.
Last Friday the acquisition vehicle announced its first purchase would be award-winning SIPP provider InvestAcc, for which it has raised £36 million to secure the deal, kickstarted by a cornerstone investment from Marwyn and the vendors themselves.
The UK's six largest real estate investment trusts (REITs) have seen significant market growth, collectively increasing their market cap from £23 billion last year to £32 billion. This is attributed to mergers and acquisitions, equity issues, and easing interest rate concerns.
There is a chance that all of JPM's Super Six - SEGRO PLC (LSE:SGRO), Landsec,LondonMetric Property PLC (LSE:LMP), Unite Group PLC (LSE:UTG), Tritax Big Box REIT PLC (LSE:BBOX), and British Land Company PLC (LSE:BLND) - could be in the FTSE 100, which would improve liquidity and possibly enhance valuations.
Shares in Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) were almost 7% higher in afternoon trading after the commercial-stage pharma group 'fortified' its balance sheet with a $5.7m monetisation deal.
Under the terms of the agreement, AOP Health International, the company's major shareholder, will provide Shield with the funds in return for the right to the $11.4 million milestone payment linked to the approval of its product Accrufer in China.
Elon Musk's Tesla Inc (NASDAQ:TSLA) has got its 'mojo back', according to Wedbush, the tech-focused investment bank and dedicated follower of the EV giant.
The comments were made in the wake of the car maker's hotly anticipated second-quarter delivery data, which showed it shipped a higher-than-expected 443,956 vehicles globally in the three months to June 30.
Shell PLC (LSE:SHEL, NYSE:SHEL) has been added to Canadian broker RBC’s Energy Best Ideas list, reflecting clarity on the message from management, strong operational performance and a discounted valuation.
Shell generates significant amounts of cash, noted RBC, supported by its oil leverage and number-one presence in LNG.
Greatland Gold PLC's (AIM:GGP, OTC:GRLGF) appointment of Dean Horton as CFO is timely as the miner nears a pivotal stage in its Havieron gold-copper development in the Pilbara region of Australia.
A definitive feasibility study on the project, due in 2024, and a full project funding solution to come are the next key steps.
BP PLC (LSE:BP.) is due for a slow re-rating from this point onwards, suggests UBS, as self-help measures and a steady retreat from its green initiatives feed through into higher earnings.
Debt concerns are also overdone says the Swiss bank, with risks now to the upside in its view.
British booze maker Diageo PLC (LSE:DGE) has hardly been in high spirits this year, with the FTSE 100-listed multinational’s share price falling more than 10% in the first half.
But with destocking headwinds settling down and the prospect of positive earnings momentum in the upcoming financial year, Diageo shares may currently offer a cheap round for patient investors.
Shares of Aptamer Group PLC (AIM:APTA) were up 12% after announcing a new collaboration with AstraZeneca PLC (LSE:AZN) to explore the use of Optimer technology for targeted delivery of siRNA, a type of genetic material used in therapies.
Optimers are synthetic molecules designed to bind specifically to target cells, enhancing the delivery and effectiveness of treatments.